Patent ID: 8252902

Claim:
An antibody targeting compound comprising a therapeutic targeting agent at least 500 daltons in size covalently linked to the combining site of a catalytic antibody via a linker of the formula X—Y—Z, such that X is a linear or branched connecting chain of atoms comprising any of C, H, N, O, P, S, Si, F, Cl, Br, and I, or a salt thereof, and Y is an optional recognition group; and Z is a reactive group wherein the catalytic antibody is an aldolase antibody having a reactive lysine residue at its combining site; wherein the targeting agent is linked to the X group of the linker; and whereby a side chain of the reactive lysine residue reacts with the beta lactam ring to form an amide linkage, and wherein the linkage forms an irreversible covalent bond.